07:00 , Jun 13, 2016 |  BC Week In Review  |  Clinical News

CC-115: Phase I data

Top-line data from 82 evaluable patients with relapsed or refractory advanced solid tumors and hematological malignancies in a 2-part, open-label, international Phase Ia/Ib trial showed that oral CC-115 led to 1 complete response in a...
07:00 , Jul 25, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Ataxia telangiectasia mutated (ATM); DNA-dependent protein kinase (DNA-PK) Mouse and cell culture studies suggest inhibiting the...